抄録
The diagnosis of IgA nephropathy (IgAN) is based on the renal biopsy that contributes with other clinical and laboratory parameters to predict the outcome of the disease. This review describes the different risk scores used to estimate the development of end-stage kidney disease and the different approaches to treat IgAN patients. Finally, according to KDIGO guidelines, some recommendations based on the renal biopsy report and laboratory data are suggested by the author for the therapy of the disease.
